Cost analysis of cryotherapy for metastatic disease

摘要

Bang and colleagues (1,2) have published their experience with percutaneous cryoablation for metastatic disease arising from non-small-cell lung carcinoma (NSCLC) (1) as well as renal cell carcinoma (2). In the first study (1), the authors describe results from 49 cryoablation procedures in 31 patients with metastatic NSCLC involving a variety of extrapulmonary sites. In this analysis, mean overall survival was 1.33 years with relatively few (8%) local recurrences, and the complication profile was favorable (8% grade 3 according to Common Terminology Criteria for Adverse Events of the National Cancer Institute, version 3). In the second study (2), the authors describe outcomes from 60 cryoablation procedures in 27 patients with metastatic renal cell carcinoma; results in this study were even more favorable, with mean overall survival of 2.69 years, a local recurrence rate of 3%, and severe complications noted in 2% of subjects.